Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Methods Mol Biol. 2021;2193:41-48. doi: 10.1007/978-1-0716-0845-6_5.
Despite significant advances in diabetic wound management, diabetic wounds remain a significant global problem that decreases patient's quality of life, and chronic wounds may lead to amputation and death to the patients. To develop a potential regenerative therapy, a xenogeneic transplantation compatible laboratory model needs to be developed. This procedure demonstrates how to isolate hematopoietic stem cells (CD133) from human umbilical cord blood, expand CD34 stem cells using a nanofiber scaffold (polyether sulfone-coated and amino group-treated), induce diabetes in immunocompromised (NOD/SCID) mice, induce a cutaneous wound in mice, and how to treat the wound with the nanofiber-expanded CD34 stem cells. This protocol also shows how to measure wound healing.
尽管在糖尿病性伤口管理方面取得了重大进展，但糖尿病性伤口仍然是一个全球性的重大问题，降低了患者的生活质量，慢性伤口可能导致患者截肢和死亡。为了开发潜在的再生治疗方法，需要开发一种与异种移植相容的实验室模型。本规程演示了如何从人脐带血中分离造血干细胞（CD133），使用纳米纤维支架（聚醚砜涂层和氨基处理）扩增 CD34 干细胞，使免疫功能低下（NOD/SCID）小鼠患上糖尿病，在小鼠中诱导皮肤伤口，以及如何用纳米纤维扩增的 CD34 干细胞治疗伤口。该方案还展示了如何测量伤口愈合。
